Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Vaccines Market Worth $94.9 billion | MarketsandMarkets™
Browse in-depth TOC on "Vaccines Market"394 - Tables57 - Figures414 - Pages Browse in-depth TOC on "Vaccines Market" 394 - Tables 57 - Figures 414 - Pages Vaccines Market Scope: The conjugate vaccine segment is expected to have the dominant share of the vaccine market (excluding COVID-19 vaccines) in 2023. Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into recombinant vaccines, conjugate vaccines, live attenuated vaccines,...
PR Newswire
24/04/2024
Ultimovacs Announces Poster Presentation at the 2024 American Society of…
NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024:Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (NCT04382664), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multicenter Phase II...
Nasdaq GlobeNewswire
24/04/2024
PHARMANUTRA: SUCROSOMIAL® TECHNOLOGY ARRIVES IN UNITED STATES
The Italian company's initial success inthe United States, where it has already obtained numerous patent and scientific recognitions from the medical community over many years, has come as a result of the effectiveness of the proprietary technologies which form the basis of the formulation of the products with which, in just 20 years, it has achieved leadership in the Italian market and significant shares of the foreign markets where it operates through exclusive distributors...
PR Newswire
24/04/2024
Unity Health Toronto partners with Cure51 to identify the biological…
As the newest addition to Cure51's extensive network of over 50 medical partners globally, Unity Health Toronto brings a wealth of expertise and resources to the project. With a shared commitment to advancing medical innovation and improving patient outcomes, this partnership is poised to drive groundbreaking discoveries in the field of oncology. Cure51 is building the first global clinical and multi omics database of exceptional survivors with over 1100 patients from all continents...
PR Newswire
24/04/2024
RenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge…
LOS ANGELES and AMSTERDAM, April24, 2024(GLOBE NEWSWIRE) -- Renovaro Inc. (Nasdaq: RENB), a trailblazer in AI-driven early cancer diagnostics and therapeutics, and Cyclomics, a leader in ultra-sensitive 4th generation multi-omics molecular biology, proudly announce a significant milestone in their collaboration. RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing...
Nasdaq GlobeNewswire
24/04/2024
Novo Nordisk A/S - Articles of Association, April 2024
Novo Nordisk's Articles of Association, April 2024 Attachment Articles of Association 24 Apr 2024
Nasdaq GlobeNewswire
24/04/2024
Novo Nordisk A/S – Reduction of the share capital
Bagsværd, Denmark, 24 April 2024– At Novo Nordisk's Annual General Meeting on 21 March 2024, it was decided to reduce the company's B share capital from DKK 343,512,800 to DKK 339,012,800 by cancellation of part of the company's portfolio of own B shares equal to a nominal value of DKK 4,500,000 divided into 45,000,000 B shares of DKK 0.10 each. Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled B...
Nasdaq GlobeNewswire
24/04/2024
Lykos Therapeutics Announces Completion of European Phase 2 Study for…
"Given the substantial need for new treatment options for individuals with mental health conditions in Europe, the completion of this Phase 2 study is an important step to helping address unmet needs outside the United States," said Amy Emerson, chief executive officer at Lykos Therapeutics. "By pursuing FDA approval of MDMA-assisted therapy first, we believe the learnings will be beneficial as we determine our regulatory strategy in the United Kingdom and Europe. We are exploring…
PR Newswire
24/04/2024
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth…
2023 business growth serving patient needs 2023 business growth serving patient needs Chiesi reached over €3 billion in sales – a 10% growth (+12% @CER) on the previous year – maintaining an EBIDTA of approximately 30% for the fourth consecutive year. In 2023, the Company reinforced its strong momentum across geographies and business areas. At constant exchange rates (@CER), growth was observed in all three of the Group's business areas (AIR - respiratory diseases, RARE - rare and...
PR Newswire
24/04/2024
Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680…
Vibrance-1 is a phase 2, randomized, double-blind, dose-range-finding, placebo-controlled study evaluating the safety and efficacy of ALKS 2680 in people with NT1. Participants will be randomized to receive one of three doses of ALKS 2680 (4 mg, 6 mg or 8 mg) or placebo to be taken once-daily for six weeks. The primary endpoint will assess whether participants taking ALKS 2680 experience a greater decrease in sleepiness compared to participants taking placebo alone, as measured by the change in…
PR Newswire
24/04/2024
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License…
Program is the Product of a Research Collaboration between Biolojic Design and Nektar entered in 2021 The antibody program selected for development (now known as NKTR-0165) is designed to modulate the TNFR2 pathway in order to agonize - or activate - T regulatory cells and other anti-inflammatory cell populations, making this a promising approach to stimulating the immune system in ulcerative colitis, multiple sclerosis, vitiligo, and other autoimmune disease states. Under the 2021...
Nasdaq GlobeNewswire
24/04/2024
Pharma Parenteral Packaging Market in the North America is Anticipated to…
Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Get Free Sample Report Pages: https://www.insightaceanalytic.com/request-sample/2446 Pharma parenteral packaging is created to hold and transport sterile pharmaceutical goods administered through injections. These packaging techniques keep medical products safe, contamination-free, and undamaged in storage, and transit and maintain their potency. The growing pharmaceutical sector, increasing...
PR Newswire
24/04/2024
Esaote Group: Shareholders' Meeting approves financial statements as of 31…
All the main Group consolidated figures for the 2023 financial year are up: net sales revenues at€ 273.2 million( +6.5%on 2022);EBITDA at€ 41.7 million( +24.5%on 2022) ; Group operating income at€ 13.4 million,( +43%on 2022);consolidated net profit at€ 6.2 million,quadrupled compared to 2022 ( € 1.2 million). " The FY2023 results confirmfurther progress of theGroup , which continues to expand, as evidenced by the 7.6% average annual growth we...
PR Newswire
24/04/2024
TVM Capital Healthcare Announces US$ 17 Million Investment into neurocare
neurocare, through its digital therapy platform (DTP), provides a holistic and patient centric treatment for a variety of psychological or neurological conditions. It uses innovative mental health care methods and tools including sleep assessment, therapeutics, psychotherapy, TMS and neurofeedback, all supervised within a cloud-based solution, to empower clinicians and deliver individualized care. Following a detailed assessment of the patient's condition, neurocare supports clinicians in…
PR Newswire
24/04/2024
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05…
The confirmatory clinical safety and efficacy study for AVT05, biosimilar candidate to Simponi® and Simponi Aria® (golimumab), met its primary endpoint in patients with moderate to severe rheumatoid arthritisAlvotech is the first company to publicly announce positive topline results from a patient study evaluating a biosimilar candidate to Simponi or Simponi Aria Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar...
Nasdaq GlobeNewswire
24/04/2024
Bioforum the Data Masters Introduces SUBMIT24: A Free of Charge and…
SUBMIT24 is proud to align with the Clinical Data Interchange Standards Consortium (CDISC), a global nonprofit organization that develops and maintains standards for clinical research. Built on the CDISC standards, SUBMIT24 is designed to streamline the data validation process and enhance efficiency in clinical research. With its user-friendly interface and advanced features, SUBMIT24 empowers users to validate clinical data with ease and accuracy. SUBMIT24 is proud to align with the Clinical...
PR Newswire
24/04/2024
Calliditas Announces Positive NefIgArd Open Label Extension Results
The OLE study was designed to provide 9 months of treatment with Nefecon for all patients who completed the NefIgArd study and who at that time had > 1g/g of proteinuria over 24h and > 30 ml/min of eGFR. All enrolled OLE patients continued on optimized RAS inhibitor therapy (ACEs and/or ARBs) and were treated for 9 months with Nefecon 16mg per day, with a follow-up visit three months after completion of treatment. Primary assessment was based on UPCR and eGFR at 9 months. A total of 119…
PR Newswire
24/04/2024
Tetra Pharm Technologies and Glysious Announce Collaboration to Develop…
Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to reach their desired targets. Glysious has worked rigorously on the development of an adhesive patch for transdermal drug delivery since the company's incorporation in 2020. Tetra Pharm Technologies has focused intensively on formulation expertise, that is, how the molecules are effectively integrated with a drug delivery system to…
PR Newswire
24/04/2024
Precision oncology company Flindr Therapeutics announces €20 million Series A…
The Company utilizes the "ImmunoGram Drug Discovery Engine", which has evolved from seminal work in the laboratories of the Netherlands Cancer Institute (NKI) and the Oncode Institute. This approach involves reverse-translating the heterogeneity in tumor-specific and host-specific factors, as commonly seen in patients in the clinic, into lab-based biological models to screen for and select the most important drug targets involved in patient clinical response. The Company utilizes…
PR Newswire
24/04/2024
135th Canton Fair Showcases Revolutionary Home Furnishing Innovations
ShenZhen ZhongShen AI DI Bedding Technology, stands at the forefront of bedding innovation driven by research and development, producing over 3000 new mattress designs annually including eco-friendly glue-free mattresses, AI smart mattresses, and natural wool mattresses. Their presented technology includes AI intelligent mattress series, leverages AI technology to instantly adapt to users' body characteristics providing an optimized sleep experience through vibration waves combined with sound…
PR Newswire
24/04/2024
SciBase Partners with Al Shirawi Healthcare solutions to Offer Nevisense in UAE
"We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a well-resourced and knowledgeable ally will enable quick market access at a low investment cost. We see this as a way to increase our reach and help more people receive the best care possible," says Pia Renaudin, CEO at SciBase "We see the UAE as an attractive market with a passion for state-of-the-art, groundbreaking technologies. Partnering up with a…
PR Newswire
24/04/2024
Groupe Casino: The New Casino embarks on its transformation plan
The New Casino embarks on its transformation plan An organisation aligned with Casino Group's new scope 1Pooling of support services between brandsRe-internalisation of skillsPlan to strengthen purchasing partnerships with Intermarché and extend such partnerships to AuchanAn employment protection plan that is balanced among the various sites More than 1,000 jobs retained at the Saint-Étienne head officeBetween 1,293 and 3,267 job losses expected A proposed...
Nasdaq GlobeNewswire
24/04/2024
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial results, for the period ended March 31, on Wednesday, May 8, 2024. Pharming will host a presentation for analysts and investors at 13:30 CEST/07:30 am EDT on May 8, 2024. To participate in the conference call, please register in advance using the link below. Once registered, dial-in information...
Nasdaq GlobeNewswire
24/04/2024
Vistin Pharma ASA: First quarter 2024 financial results
thof April 2024Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024.Revenue in the first quarter ended at MNOK 104 compared to MNOK 101 in Q1 2023. Sales volume in the quarter was up by 11% compared to Q1 2023.First quarter EBITDA ended at MNOK 20 compared to MNOK 14 in Q1 2023, representing a 45% increase. EBITDA positively affected by increased sales volume and product mix, partly offset by a one-time inventory adjustment of MNOK 7.The net...
Nasdaq GlobeNewswire
24/04/2024
Altri Comunicati